1
|
Cousins MM, Dykstra MP, Griffith K, Mietzel M, Kendrick D, Trumpower E, Dusseau D, Dominello MM, Boike TP, Hayman JA, Walker EM, Jolly S, Mierzwa ML, Jagsi R, Vicini FA, Pierce LJ. Cannabis Use Patterns among Patients with Early-Stage Breast Cancer in a Large Multicenter Cohort from a State with Legalized Adult Non-Medical Cannabis. Int J Radiat Oncol Biol Phys 2023; 117:e95. [PMID: 37786222 DOI: 10.1016/j.ijrobp.2023.06.858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Cannabis use among patients with cancer is an area of great interest given its widespread acceptance despite the lack of supporting clinical data. The absence of data limits the understanding of potential clinical benefits of cannabis and the ability of providers to deliver evidence-based recommendations for patient care. We explored cannabis use patterns in patients with early-stage breast cancer in a large multicenter cohort in a state with legalized adult non-medical cannabis. MATERIALS/METHODS Initial questions about cannabis use history and frequency were introduced in Michigan Radiation Oncology Quality Consortium (MROQC) breast cancer patient surveys on 2/1/2020 for female patients receiving radiation after lumpectomy for non-metastatic breast cancer. Expanded questions were introduced on 6/28/2022 to assess mode of administration, active ingredient, and reason for use. Summary statistics were generated. A multivariable model using logistic regression identified patient characteristics associated with cannabis use. RESULTS Among 3948 eligible patients, 2738 (69.35%) completed survey questions, and 2462/2738 (89.9%) completed the initial question on cannabis use. Among those, 364/2462 (14.8%) noted cannabis use in the last 30 days, 588 (23.9%) noted remote use (>30 days ago), 1462 (59.4%) reported never having used cannabis, 44 (1.8%) preferred not to answer cannabis use questions, and 4 (0.4%) did not provide use history. Younger age [age <50 vs 60-70, OR 2.5 (95% CI 1.65, 3.79) p<0.001)], Hispanic ethnicity [OR 2.20 (95% CI 1.06, 4.56) p = 0.03], history of smoking [OR 2.56 (95% CI 1.88, 3.48) p<0.001], current smoking [OR 4.70 (95% CI 3.22, 6.86) p<0.001)], and prior chemotherapy [OR 1.40 (95% CI 1.00, 1.96) p = 0.05] predicted recent cannabis use in a multivariable model. Of the 364 patients endorsing cannabis use in the last 30 days, 89 (24.5%), 72 (19.8%), 29 (8.0%), 66 (18.1%), 30 (8.2%), and 78 (21.4%) reported using cannabis 1-2 days, 3-5 days, 6-9 days, 10-19 days, 20-29 days, and all 30 days, respectively. The most common modes of administration among 76 individuals who responded to the expanded questionnaire to date were oral (39.4%), smoking (30.3%), and topical (10.5%). The products used contained tetrahydrocannabinol (THC; 26.3%), cannabidiol (CBD; 19.7%), balanced levels of THC and CBD (19.7%), or active ingredients that were unknown to the patient (34.2%). Patients frequently endorsed cannabis use for insomnia, anxiety, and pain. CONCLUSION Many patients with early-stage breast cancer are using cannabis. Younger age, Hispanic ethnicity, smoking, and chemotherapy history are predictors of cannabis use. Patients are often unaware of the active ingredients in the products that they use, suggesting an important role for patient education and a need to equip providers to advise patients in their care.
Collapse
Affiliation(s)
- M M Cousins
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Department of Radiation Oncology, Self Regional Healthcare, Greenwood, SC
| | - M P Dykstra
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - K Griffith
- Department of Biostatistics, University of Michigan, Ann Arbor, MI; Michigan Radiation Oncology Quality Consortium Coordinating Center, Ann Arbor, MI
| | - M Mietzel
- Michigan Radiation Oncology Quality Consortium Coordinating Center, Ann Arbor, MI
| | - D Kendrick
- Michigan Radiation Oncology Quality Consortium Coordinating Center, Ann Arbor, MI
| | - E Trumpower
- Michigan Radiation Oncology Quality Consortium Coordinating Center, Ann Arbor, MI
| | - D Dusseau
- Department of Radiation Oncology, Henry Ford Health System, Jackson, MI
| | - M M Dominello
- Department of Radiation Oncology, Karmanos Cancer Center, Detroit, MI
| | - T P Boike
- Department of Radiation Oncology, GenesisCare, Farmington Hills, MI
| | - J A Hayman
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - E M Walker
- Department of Radiation Oncology, Henry Ford Health System, Detroit, MI
| | - S Jolly
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - M L Mierzwa
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - R Jagsi
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Department of Radiation Oncology, Emory University, Atlanta, GA
| | - F A Vicini
- Department of Radiation Oncology, GenesisCare, Farmington Hills, MI
| | - L J Pierce
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| |
Collapse
|
2
|
Moncion A, Griffith K, Walker EM, Jagsi R, Dominello MM, Wilson M, Mietzel M, Grubb M, Marsh R, Vicini FA, Pierce LJ. Impact of Breast Volume on Achieving a Conservative Heart and Target Coverage Metric for Patients Receiving Whole Breast Radiotherapy in a Statewide Consortium. Int J Radiat Oncol Biol Phys 2023; 117:e193-e194. [PMID: 37784833 DOI: 10.1016/j.ijrobp.2023.06.1061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Radiation to large breast volumes (BV) has been associated with increased dose inhomogeneities, breast fibrosis, and induration. Radiation exposure to the heart during breast radiotherapy has been associated with late cardiovascular morbidity and mortality. This study, therefore, investigates the impact of BV on achieving optimal lumpectomy cavity target coverage (V95% [%] >95) while maintaining mean heart dose constraints (MHD, mean [Gy] <1) across a range of BV from patients enrolled in a statewide consortium. MATERIALS/METHODS A retrospective analysis was conducted for 2,506 patients receiving left-sided whole breast moderately-hypofractionated (2.5-2.8 Gy/fx) radiotherapy without nodal fields between 2018-2022. The BV was calculated for each patient from contours in the treatment planning system, and the volume distribution partitioned into quartiles. Dosimetric parameters were calculated from dose-volume histograms. The percentage of patients in which the metrics were achieved was calculated for each BV quartile for different treatment positions: all positions, supine, supine with breathing motion management, and prone. RESULTS The BV ranges within the quartiles (∼620 patients/quartile) were ≤720.0 cc, 720.1 to ≤1065.0 cc, 1065.1 to ≤1500.0 cc, and >1500.0 cc for quartiles Q1-Q4, respectively. Of the 2,506 patients, 76% were treated supine (of which 41.6% were treated using breathing motion management techniques), 23.5% were treated prone, and 0.5% were treated decubitus. Discrete percentages of patients able to meet the metrics are provided in the table. An increase in BV from Q1 to Q4 correlated with lower percentages of patients meeting the MHD metric, however no correlation was observed between BV and target coverage. Treating supine with breathing motion management resulted in a higher percentage of patients meeting the MHD metric (odds ratio (OR) = 1.96 relative to supine without motion management, p<0.0001), while the prone setup proved to be the superior technique across all quartiles (OR = 3.95 relative to supine, p<0.0001). CONCLUSION Increasing BVs resulted in lower percentages of patients receiving MHD≤1 Gy. Thus, cardiac sparing may be more difficult to achieve in patients with larger BV. Utilization of alternate treatment positions, such as supine with breathing motion management and prone, greatly improved the percentage of patients able to meet the MHD metric without sacrificing target coverage in all quartiles. Prone positioning was the technique least susceptible to BV effects in meeting the MHD≤1 Gy goal.
Collapse
Affiliation(s)
- A Moncion
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - K Griffith
- Department of Biostatistics, University of Michigan, Ann Arbor, MI
| | - E M Walker
- Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI
| | - R Jagsi
- Department of Radiation Oncology, Emory University, Atlanta, GA
| | - M M Dominello
- Department of Radiation Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI
| | - M Wilson
- MHP Radiation Oncology Institute/GenesisCare, Farmington Hills, MI
| | - M Mietzel
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - M Grubb
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - R Marsh
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - F A Vicini
- MHP Radiation Oncology Institute/GenesisCare, Farmington Hills, MI
| | - L J Pierce
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| |
Collapse
|
3
|
Herr DJ, Moncion A, Griffith K, Marsh R, Grubb M, Bhatt AK, Dominello MM, Walker EM, Narayana V, Abu-Isa EI, Vicini FA, Hayman JA, Pierce LJ. Factors Associated with Cardiac Radiation Dose Reduction Following Hypofractionated Radiation Therapy for Localized, Left-Sided Breast Cancer in a Large Statewide Quality Consortium. Int J Radiat Oncol Biol Phys 2023; 117:S138. [PMID: 37784352 DOI: 10.1016/j.ijrobp.2023.06.544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Limiting radiation dose to the heart is important for minimizing the risk of long-term cardiac toxicity in patients with left-sided early-stage breast cancer. MATERIALS/METHODS Prospectively collected dosimetric data were analyzed for patients undergoing hypofractionated radiation therapy to the left breast for localized node-negative breast cancer within the Michigan Radiation Oncology Quality Consortium (MROQC) from 2016-2022. Goals for limiting cardiac dose were adjusted over time. From 2016-2020, the cardiac quality metric focused on total mean heart dose (MHD) from the composite whole breast and boost plans, tightening from a goal of MHD ≤2 Gy to MHD ≤1.2 Gy by 2020. In 2021-2022, the cardiac metric transitioned to a combined goal of MHD ≤1.0 Gy from the whole breast plan and ≥95% lumpectomy cavity planning target volume (PTV) receiving 95% of the prescription dose. Separate multivariate logistic regression models were developed to assess for covariates associated with meeting the MHD goal in 2016-2020 and combined MHD/PTV coverage goal in 2021-2022. RESULTS In total, 4,165 patients were analyzed with a median age of 64 years. Most patients (86%) had either Tis or T1 disease, and 66% received hormone therapy. Baseline demographic and disease characteristics did not change substantially between treatment periods. Use of breath-hold or motion gating increased from 42% in 2016-2020 to 46% in 2021-2022. Similarly, use of prone positioning increased from 12% to 20%. From 2016-2020, 90.9% of plans achieved the MHD goal, compared to 93.6% of plans achieving the composite MHD/PTV goal from 2021-2022. On multivariate analysis in the 2016-2020 cohort, treatment with motion management (OR 5.20, 95% CI [3.59-7.54], p<0.0001) or prone positioning (OR 3.21, 95% CI [1.85-5.57], p < 0.0001) were associated with meeting the MHD goal, while receipt of boost (OR 0.25, 95% CI [0.17-0.39], p<0.0001) and omission of hormone therapy (OR 0.65, 95% CI [0.49-0.88], p = 0.0047), were associated with not meeting the MHD goal. During the era including composite heart dose and PTV coverage goals (2021-2022), treatment with motion management (OR 1.89, 95% CI [1.12-3.21], p = 0.018) or prone positioning (OR 3.71, 95% CI [1.73-7.95], p = 0.0008) were associated with meeting the combined goal, while larger breast volume (≥1440 cc, OR 0.34, 95% CI [0.13 - 0.91], p = 0.031) and treatment at an academic center (OR 0.36, 95% CI [0.22-0.67], p = 0.0009) were associated with not meeting the combined goal. CONCLUSION In our statewide consortium, rates of compliance with aggressive targets for limiting cardiac dose remain high, despite tightening of these goals to include lower mean heart doses and inclusion of a concurrent PTV coverage goal. Treatment using motion management or prone positioning is associated with achieving the cardiac dose goals.
Collapse
Affiliation(s)
- D J Herr
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - A Moncion
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - K Griffith
- Department of Biostatistics, University of Michigan, Ann Arbor, MI
| | - R Marsh
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - M Grubb
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - A K Bhatt
- Karmanos Cancer Institute at McLaren Greater Lansing, Lansing, MI
| | - M M Dominello
- Department of Radiation Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI
| | - E M Walker
- Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI
| | - V Narayana
- Ascension Providence Hospital, Southfield, MI
| | - E I Abu-Isa
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Ascension Providence Hospital, Southfield, MI
| | - F A Vicini
- MHP Radiation Oncology Institute/GenesisCare, Farmington Hills, MI
| | - J A Hayman
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - L J Pierce
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| |
Collapse
|
4
|
Herr DJ, Yin H, Bergsma DP, Dragovic AF, Matuszak MM, Grubb M, Dominello MM, Movsas B, Kestin LL, Boike TP, Bhatt AK, Hayman JA, Jolly S, Schipper M, Paximadis PA. Dosimetric Predictors for Acute Esophagitis during Radiation Therapy for Lung Cancer: An Update of a Large Statewide Observational Study. Int J Radiat Oncol Biol Phys 2023; 117:e24. [PMID: 37784947 DOI: 10.1016/j.ijrobp.2023.06.700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Acute esophagitis remains a clinical challenge during the treatment of locally advanced non-small cell lung cancer (NSCLC). Here, we analyze the dosimetric and patient-level characteristics associated with acute grade 2+ and 3+ esophagitis in patients undergoing radiation therapy for NSCLC across a statewide consortium. MATERIALS/METHODS Demographic, dosimetric, and acute toxicity data were prospectively collected for patients undergoing definitive radiation therapy +/- chemotherapy for stage II-III NSCLC from 2012-2022 across the Michigan Radiation Oncology Quality Consortium (MROQC). Logistic regression models were used to characterize the risk of grade 2+ and 3+ esophagitis as a function of dosimetric and clinical covariates. Multivariate regression models were fitted to predict the 50% risk of grade 2 esophagitis or 3% risk of grade 3 esophagitis at each dose value. RESULTS Of 1760 patients evaluated, 84.2% had stage III disease and 85.3% received concurrent chemotherapy. 79.2% of patients had an ECOG performance status ≤1. Rates of acute grade 2+ and 3+ esophagitis were 48.4% and 2.2%, respectively. On multivariate analyses, performance status, mean esophageal dose and esophageal D2cc were significantly associated with grade 2+ and 3+ esophagitis. Concurrent chemotherapy was associated with grade 2+ but not grade 3+ esophagitis. Dose-response relationships were modeled for grade 2+ and 3+ esophagitis by mean esophageal dose and esophageal D2cc, stratified by performance status and/or receipt of concurrent chemotherapy. For all patients, mean esophageal dose of 29 Gy and esophageal D2cc of 61 Gy corresponded to a 3% risk of acute grade 3+ esophagitis. For patients receiving chemotherapy, mean esophageal dose of 22 Gy and esophageal D2cc of 49.5 Gy corresponded to a 50% risk of acute grade 2+ esophagitis. CONCLUSION Performance status, concurrent chemotherapy, mean esophageal dose and esophageal D2cc are associated with acute esophagitis during definitive treatment of NSCLC. Models that quantitatively account for these factors can be useful in individualizing radiation plans. Mean esophageal dose of 29 Gy and esophageal D2cc of 61 Gy corresponded to a 3% risk of acute grade 3+ esophagitis and merit consideration as contemporary treatment planning constraints.
Collapse
Affiliation(s)
- D J Herr
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - H Yin
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - D P Bergsma
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Department of Radiation Oncology, Mercy Health Saint Mary's, Grand Rapids, MI
| | - A F Dragovic
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Department of Radiation Oncology, Brighton Center for Specialty Care, Brighton, MI
| | - M M Matuszak
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - M Grubb
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - M M Dominello
- Department of Radiation Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI
| | - B Movsas
- Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI
| | - L L Kestin
- Michigan Healthcare Professionals/Genesis Care USA, Farmington Hills, MI
| | - T P Boike
- GenesisCare USA / Michigan Healthcare Professionals, Troy, MI
| | - A K Bhatt
- Karmanos Cancer Institute at McLaren Greater Lansing, Lansing, MI
| | - J A Hayman
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - S Jolly
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | - M Schipper
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; Department of Biostatistics, University of Michigan, Ann Arbor, MI
| | - P A Paximadis
- Department of Radiation Oncology, Corewell Health South, St. Joseph, MI
| |
Collapse
|